Cargando…

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response

BACKGROUND. The ability to make early therapeutic decisions when treating invasive aspergillosis using changes in biomarkers as a surrogate for therapeutic response could significantly improve patient outcome. METHODS. Cox proportional hazards model and logistic regression were used to correlate ear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovanda, Laura L., Kolamunnage-Dona, Ruwanthi, Neely, Michael, Maertens, Johan, Lee, Misun, Hope, William W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434340/ https://www.ncbi.nlm.nih.gov/pubmed/28472247 http://dx.doi.org/10.1093/cid/cix198

Ejemplares similares

Isavuconazole Pharmacokinetics and Pharmacodynamics in Children
por: Elhence, Hirsh, et al.
Publicado: (2022)

Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus
por: Negri, Clara E, et al.
Publicado: (2018)

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
por: Kovanda, Laura L., et al.
Publicado: (2019)

Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole
por: Kovanda, Laura L., et al.
Publicado: (2017)

Isavuconazole for COVID-19-Associated Invasive Mold Infections
por: Ullah, Nadir, et al.
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age
por: Mercier, Toine, et al.
Publicado: (2018)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

1149. Baseline Chest CT Findings in Patients with Pulmonary Mold Infections: A Post-Hoc Analysis from the Phase 3 SECURE Study that Compared Isavuconazole to Voriconazole for the Primary Treatment of Invasive Mold Disease
por: Hamed, Kamal, et al.
Publicado: (2020)

850. Real-world effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients
por: Qiu, Ye, et al.
Publicado: (2023)

Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei
por: Le, Thuy, et al.
Publicado: (2019)

1210 A Phase 3, Randomized, Double-Blind, Non-inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients
por: Patterson, Thomas, et al.
Publicado: (2014)

Investigation of 2‐stage meta‐analysis methods for joint longitudinal and time‐to‐event data through simulation and real data application
por: Sudell, Maria, et al.
Publicado: (2017)

Investigation of one‐stage meta‐analysis methods for joint longitudinal and time‐to‐event data through simulation and real data application
por: Sudell, Maria, et al.
Publicado: (2018)

Editorial Commentary: Galactomannan Testing During Mold-Active Prophylaxis
por: Cornely, Oliver A.
Publicado: (2014)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses
por: Thompson, George R., et al.
Publicado: (2016)

Breaking the mold: A case of pulmonary mucormycosis treated with isavuconazole
por: Huggins, Jonathan, et al.
Publicado: (2018)

A Mortality Prediction Rule for Hematology Patients with Invasive Aspergillosis Based on Serum Galactomannan Kinetics
por: Mercier, Toine, et al.
Publicado: (2020)

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease
por: Hope, William W., et al.
Publicado: (2017)

Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
por: Bagshaw, Emma, et al.
Publicado: (2018)

Invasive Mold Infections Following Hurricane Harvey—Houston, Texas
por: Toda, Mitsuru, et al.
Publicado: (2023)

Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system
por: Schwartz, Stefan, et al.
Publicado: (2020)

Evaluating statistical characteristics of biomarker-guided trial designs
por: Antoniou, Miranta, et al.
Publicado: (2015)

Sample size formula for joint modelling of longitudinal and time-to-event data in clinical trials
por: Powney, Matthew, et al.
Publicado: (2013)

Adjusting for informative missing outcome data in clinical trials with longitudinal study designs
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2013)

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
por: Kovanda, Laura L., et al.
Publicado: (2016)

Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children
por: Lehrnbecher, Thomas, et al.
Publicado: (2019)

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2016)

Modelling variable dropout in randomised controlled trials with longitudinal outcomes: application to the MAGNETIC study
por: Kolamunnage-Dona, Ruwanthi, et al.
Publicado: (2016)

Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
por: Sudell, Maria, et al.
Publicado: (2016)

Correction to: joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis
por: Sudell, Maria, et al.
Publicado: (2018)

Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1
por: Antoniou, Miranta, et al.
Publicado: (2018)

Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7, 19
por: Antoniou, Miranta, et al.
Publicado: (2018)

Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size
por: Antoniou, Miranta, et al.
Publicado: (2017)

Time-dependent ROC curve analysis in medical research: current methods and applications
por: Kamarudin, Adina Najwa, et al.
Publicado: (2017)

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2017)

Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results From a Subgroup Analysis of a Multicenter National Registry
por: Nguyen, M Hong, et al.
Publicado: (2023)

Diagnosis of Histoplasmosis Using the MVista Histoplasma Galactomannan Antigen Qualitative Lateral Flow–Based Immunoassay: A Multicenter Study
por: Abdallah, Wassim, et al.
Publicado: (2021)

2537. Population Pharmacokinetics of Isavuconazole in Pediatric Patients
por: Desai, Amit, et al.
Publicado: (2023)

Isavuconazole for invasive fungal infections
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k3ei0ki4es7iusso2lmg49jv4e